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In this issue ofCancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show
that CD28-CD3z CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradi-
cation while reducing exhaustion. The results have important implications for the development of effective
CAR T cell therapies in cancer patients.Chimeric antigen receptors (CARs) com-
bine an antibody-derived extracellular
domain with intracellular signaling do-
mains that promote immune cell activa-
tion and function. T cells transduced
with CARs can be effectively redirected
to and activated by a target antigen.
‘‘Second generation’’ CARs containing
the cytoplasmic signaling domains of
CD3z and co-stimulatory (CD28 and
4-1BB) receptors have been used suc-
cessfully to treat multiple blood cancers
(Zhang et al., 2015). The presence of
costimulatory domains vastly improved
tumor eradication compared to CARs
with CD3z alone, largely due to the induc-
tion of survival signals and prevention of
anergy (Kowolik et al., 2006).
While T cells expressing either CD28- or
4-1BB-containing CARs have achieved
many complete remissions, the 4-1BB
design appears to favor persistence,
with CAR T cells detectable out to at least
6 months in a majority of patients,
whereas the CD28 CAR T cells were
typically undetectable beyond 3 months
(Zhang et al., 2015). Interim analysis
suggests that there is less severe cyto-
kine release syndrome and a lower
CD19-negative relapse rate using the
CD28 CAR T cells (C.H. June et al.,
2014, Am. Soc. Hematol., abstract). How-
ever, most of the patients in this trial went
on to receive curative allogeneic stem
cell transplants, so they are lost to long-
term follow-up to conclusively determine
relapse rate. There also have been no
controlled direct comparisons, so differ-
ences could reflect other variables in-
cluding patient population, population of
T cells used as therapeutics, CAR trans-
duction approaches, and CD19-specificantibodies used as the extracellular do-
mains. That said, many groups are forging
ahead to develop more effective con-
structs for human therapy. These efforts
will require better and more predictive
in vivo models, because several CAR en-
hancements do not affect in vitro T cell ac-
tivities such as T cell exhaustion and sur-
vival (Long et al., 2015), CAR-T resistance
to suppression within the tumor microen-
vironment, or induction of suppressive
regulatory T cells (Tregs) (de Aquino et al.,
2015).
CAR T cells that constitutively ex-
pressed the ligands for CD28 (CD80)
and 4-1BB (4-1BBL) also significantly
boosted T cell proliferation and tumor
eradication in vivo (Stephan et al., 2007).
Previous studies revealed that CARs con-
taining both the CD28 and 4-1BB do-
mains enhanced tumor eradication and
persistence in mouse models (Zhong
et al., 2010). These findings raise the pos-
sibility that the CD28 and 4-1BB signals
could be delivered either directly into the
T cells or indirectly in the tumor milieu to
promote aggressive anti-tumor immunity.
However, no one had compared whether
costimulation provided directly through a
CAR confers unique advantages or disad-
vantages to constitutive ligand expres-
sion. In this issue of Cancer Cell, Zhao
et al. (2015) explore the differences and
synergies between CD28 and 4-1BB
costimulation in CAR-T cells by system-
atically exploring third-generation CAR
T cells that contain multiple co-stimula-
tory modules and/or ligands with CD3z.
These efforts were coupled with robust
in vivo modeling to discriminate between
simple enhancement of cytolytic activity
and characteristics that reflect CAR supe-Cancer Cell 28riority in promoting tumor elimination and
T cell persistence.
The investigators compared anti-hu-
man CD19 CARs containing CD3z alone
(19z1), CD28 and CD3z (1928z), or 4-
1BB and CD3z (19BBz). They observed
no differences in terms of cytolytic activity
and a limited enhancement of proliferation
and survival of the 19BBz-transduced
T cells in vitro. However, by using a novel
in vivo ‘‘stress test’’ approach involving
the injection of CAR T cells at numbers
low enough that CAR T treatment failed
in a significant number of animals, a direct
comparison of the constructs yielded
quite distinct kinetics. CD28-containing
CAR T cells favored tumor elimination at
earlier time points in the mouse model,
whereas 4-1BB CAR-T cells persisted
longer and eventually reached the same
level of tumor eradication.
To determine if the enhanced cytotox-
icity provided by CD28 can be combined
with the enhanced T cell proliferation and
persistence conferred through 4-1BB,
Zhao et al. (2015) designed four additional
constructs: a CAR constructed to express
both CD28 and 4-1BB costimulatory
domains (1928BBz), two CARs that
contained either the CD28 or 4-1BB
costimulatory domain while expressing
the complementary costimulatory ligand
(1928z-41BBL and 19BBz-CD80), and
aCD3zCAR that expressedboth costimu-
latory ligands (19z1-CD80-41BBL). T cells
transduced with the 1928z-41BBL con-
struct resulted in the highest CAR-T accu-
mulation, potent tumor eradication at
day 7, and complete remission at the
lowest dose of CAR T cells administered.
The investigators suggested that the
increased efficacy was due to a selective, October 12, 2015 ª2015 Elsevier Inc. 401
AB
Figure 1. Advancing CAR T Cell Designs
(A) Examples of enhancing features for T cell-based cancer immunotherapy with corresponding second-
generation chimeric antigen receptors (CARs), known surface ligands, and potential surface ligands that
might enhance these key attributes to maximize CAR T cell efficacy. Highlighted in red is the suggested
combination of CAR and surface ligand to maximize CAR T cell efficacy as modeled by Zhao et al. (2015).
(B) A model representing a CD4+ 1928z-41BBL CAR T cell and its potential interaction partners in the
tumor microenvironment based on previous work. This T cell shows the combined benefits of 4-1BB and
CD28 costimulation while also having emergent features such as specific cytokine and transcription factor
upregulation. A potential interacting cell population, Tregs, is also represented that can produce sup-
pressive cytokines and thus alter the trans effects of 4-1BBL expression.
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T cells and decreased expression of
exhaustion markers. These data are
consistent with work showing that 4-1BB
can alleviate anergy induced by tonic
CAR signaling (Long et al., 2015). Addi-
tionally, the authors noted that 1928z-
41BBL-expressing T cells express higher
amounts of type-I interferon targets,
including IRF7 and IFNb, and shRNA
knockdown of IRF7 in 1928z-41BBL
T cells significantly reduced tumor eradi-
cation and mouse survival. This change
was associated with decreased IFNg and
granzyme B expression in vitro and could
be rescued through exogenous IFNb.
Thus, the enhanced cytotoxicity pro-
vided by CD28 signaling can be success-
fully combined with the increased persis-
tence through 4-1BB signaling to make a
more potent CAR T cell (Figure 1A). The
investigators then addressed whether
the two signaling pathways needed to
go through the same CAR or could be
indirectly activated by triggering endoge-
nous CD28 and 4-1BB receptors. The re-
sults suggest that 4-1BB signals through402 Cancer Cell 28, October 12, 2015 ª2015the endogenous receptor may more
effectively enhance CAR T cell activity,
potentially in a bidirectional manner with
direct signaling within the CAR T cells
themselves and indirect triggering of
other 4-1BB+ cells in the tumormicroenvi-
ronment (either the transduced CAR
T cells or other immune cells) (Stephan
et al., 2007). Importantly, incorporation
of CD28 in the CAR may be preferred,
because it avoids the requirement for
CD28 ligand engagement, which can be
antagonized by CTLA-4 expression on
effector or Tregs (de Aquino et al., 2015).
This study advances the development
of next-generation CAR T cells, but there
remain questions that will need to be
addressed as these new constructs
are introduced into clinical applications
(Figure 1B). The immunodeficient mouse
model does not address how 4-1BBL
expression drives the activation of other
immune cells in the tumor microenviron-
ment, such as NK cells and dendritic
cells. Immunosuppressive Tregs also high-
ly express 4-1BB, although it is unclear
how or whether 4-1BB signaling benefitsElsevier Inc.Treg expansion and activity (Bartkowiak
and Curran, 2015). If this is an issue, it
will be important to determine whether
the 1928BBz CAR showed less effi-
cacy because of surface expression or a
genuine difference in signaling properties,
especially considering that the 19BBz and
19BBz-CD80 also show some IRF7 and
IFNb production.
Lastly, the in vivo ‘‘stress test’’ model
designed by Zhao et al. (2015) could eluci-
date how to best optimize CAR T cells for
treatment-resistant cancers such as solid
tumors. The potential bystander effects of
IFNb could improve cytotoxicity in the
tumor microenvironment and be used to
test CARs that would increase efficacy
for solid tumors. However, even this
model may not reflect the human setting
where the complexities of the tumor
microenvironment, coupled with distinct
expression and signaling of the various
co-stimulatory pathways, could give un-
expected outcomes. Thus, efforts to
explore future generations of CAR con-
structs will depend on continued innova-
tive approaches that can directly compare
individual and combined co-stimulatory
domains perhaps based on additional bio-
markers that can predict human in vivo
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